4-Hydroxyandrosterone

4-Hydroxyandrosterone acts primarily as an androgen receptor agonist, binding to the same receptors as testosterone but with distinct affinity characteristics. It is a metabolite of dehydroepiandrosterone (DHEA), a precursor in the adrenal androgen synthesis pathway. Unlike 17-alpha-alkylated compounds, it does not undergo significant first-pass metabolism in the liver, which may reduce hepatotoxicity concerns associated with oral administration. The compound is injected, bypassing the gastrointestinal tract entirely. In research contexts, it is examined for its ability to maintain androgenic signaling without the strong anabolic drive of testosterone esters. Users report that it supports androgenic potency by providing a steady state of receptor activation. It does not aromatize to estrogen, which distinguishes it from many other anabolic agents. This lack of aromatization means it does not contribute to estrogenic side effects like water retention or gynecomastia. The mechanism is straightforward: direct receptor binding and modulation of gene expression related to muscle protein synthesis and androgenic traits.

In athletic research, 4-Hydroxyandrosterone is typically employed in cutting or recomposition cycles rather than mass-building phases. Its primary application is to maintain androgenic signaling during periods when endogenous testosterone production is suppressed. Athletes often use it as a support compound alongside primary anabolic steroids to ensure consistent receptor activation. It is not a standalone agent for significant muscle growth due to its moderate anabolic potency. Instead, it is valued for its ability to preserve strength and muscle fullness without adding water weight. Users report that it helps maintain a 'dry' look while supporting performance. It is also studied in the context of adrenal androgen support, particularly for individuals with low DHEA levels. The compound is rarely used in bulking cycles because it does not provide the caloric surplus or nitrogen retention necessary for rapid mass gain. Its role is supportive, ensuring that androgenic pathways remain active even when primary agents are tapered or during post-cycle therapy. This makes it a niche but specific tool in advanced research protocols.

Research protocols for 4-Hydroxyandrosterone typically involve doses ranging from 200 mg to 400 mg per week. This range is considered moderate and is often sufficient to maintain androgenic signaling without excessive side effects. The compound is administered via injection, usually once or twice weekly, to maintain stable blood levels. Cycle lengths typically range from 6 to 12 weeks, depending on the primary agent being used. It is often run concurrently with testosterone or other anabolic steroids. Users report that doses below 150 mg/week may not provide significant receptor activation, while doses above 500 mg/week do not yield proportional benefits and may increase the risk of androgenic side effects. The cycle length is often aligned with the primary anabolic agent, ensuring that androgenic support is maintained throughout the protocol. It is not typically used as a standalone cycle agent. Blood work is recommended to monitor androgen levels and ensure that the dose is appropriate for the individual's baseline. Consistency in dosing is key to maintaining stable receptor activation.

While 4-Hydroxyandrosterone is not 17-alpha-alkylated, it is still an androgenic compound and carries the standard risks associated with exogenous androgen use. Users report potential side effects including acne, oiliness, and increased body hair growth. Because it does not aromatize, estrogenic side effects like water retention and gynecomastia are unlikely. However, it can suppress endogenous testosterone production, necessitating a post-cycle therapy (PCT) if used for extended periods. PCT typically involves selective estrogen receptor modulators (SERMs) like tamoxifen or clomiphene to restore natural testosterone production. Blood work is essential to monitor lipid profiles, as androgenic compounds can negatively impact cholesterol levels. Users should also monitor liver enzymes, although the risk of hepatotoxicity is lower than with oral 17-alpha-alkylated compounds. Age 21+ is recommended for research use due to the potential for long-term hormonal disruption. Individuals with a history of prostate issues or cardiovascular disease should exercise extreme caution. Regular check-ups and adherence to safety considerations are critical for minimizing risks.

Mechanism of action

4-Hydroxyandrosterone acts as an androgen receptor agonist, binding to androgen receptors to modulate gene expression related to muscle protein synthesis and androgenic traits without aromatizing to estrogen.